Parker Waichman LLP

FDA Concerned About Expanded Fentora Approval

The US Food and Drug Administration (FDA) has long been concerned over Cephalon Inc.’s marketing of Fentora, a cancer pain drug, to non-cancer patients. An FDA official said Fentora use in noncancer patients could have “devastating effects. Cephalon continues to seek FDA approval to promote Fentora—fentanyl buccal—for sudden pain in noncancer patients with an opioid tolerance. Last […]

Fentora Approval

The US Food and Drug Administration (FDA) has long been concerned over Cephalon Inc.’s marketing of Fentora, a cancer pain drug, to non-cancer patients. An FDA official said Fentora use in noncancer patients could have “devastating effects. Cephalon continues to seek FDA approval to promote Fentora—fentanyl buccal—for sudden pain in noncancer patients with an opioid tolerance.

Last September, Cephalon submitted a request to the FDA seeking approval to market Fentora for breakthrough pain management in opioid-tolerant noncancer patients. Given that Cephalon’s illegal marketing practices have been under constant scrutiny in recent years and the FDA issued a pubic warning over Fentora following reports its use led to breathing problems, deaths, and other serious complications, this was an odd request.

We are concerned that the sponsor’s request to expand the current indication for Fentora

“We are concerned that the sponsor’s request to expand the current indication for Fentora … may greatly increase the prescribing of this product which may increase the availability of the product for diversion, abuse, and misuse,” wrote Bob Rappaport, head of the FDA’s Division of Anesthesia, Analgesia, and Rheumatology Products. Rappaport added Fentora could “increase the incidence of accidental exposures which, due to the potency of the product, could potentially have devastating effects.”

In 2006, the Wall Street Journal investigated Cephalon’s marketing of Actiq—Cephalon’s other fentanyl drug sold in a lollipop form—and discovered 80 percent of patients prescribed Actiq were not cancer patients and Cephalon frequently focused marketing of Actiq to noncancer physicians in sports medicine and family practice specialties. That same year, the Connecticut Attorney General discovered Cephalon illegally marketed Actiq for off-label use and set high sales quotas that could only be met through off-label dispensing. Cephalon’s marketing of Fentora had also been under investigation by the US Attorney in Philadelphia as well as by Congress. Actiq has been linked to over 120 deaths.  In the case of Fentora, illegal marketing has been linked to four deaths, none of which occurred in cancer patients. Cephalon admitted some of these deaths were due to off-label use.

Fentora and Actiq are FDA-approved only for use in cancer patients for break-through pain—pain that occurs quickly

Fentora and Actiq are FDA-approved only for use in cancer patients for break-through pain—pain that occurs quickly, is severe, and is of short duration. Fentora is contraindicated for noncancer-related pains and for cancer patients intolerant to or not undergoing constant opioid therapy; the drug is indicated for a very specific population, is a faster acting version of Actiq, and is not a generic version of any opioid-containing drug. Because Fentora is dosed to deliver higher amounts of fentanyl—a highly addictive opiate 80 times more powerful than morphine—it is never to be substituted for any other drug since misuse at any dose can—and has—resulted in death.

The FDA is conducting an advisory meeting tomorrow with a panel of external experts regarding whether wider Fentora use should be approved. The FDA said it received reports Fentora was incorrectly prescribed, given at wrong doses, and that tablets were inappropriately substituted by doctors and pharmacists for Actiq. Cephalon told reporters, “There is no evidence that Fentora poses risks of abuse and diversion greater than other opioids.” Cephalon said it expects the FDA to make its final decision by September 13.05

Need Legal Help Regarding Fentora Approval?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Parker and Waichman are the best when handling my WTC case. The staff in particular Lawyer Ms. Shelly Davis are the ultimate professionals. Shelly Davis was empathetic and compassionate given the nature and sensitivity of my case along with being very knowledgeable of the intricacies of the WTC govern laws. I highly recommend Parker and Waichman in particular lawyer Shelly Davis. Peace and Blessings!
Allegra Maple
a year ago
5 Star Reviews 150
I found them in the yellow pages online. I had a bad care accident and out of work for months. They walked me through the legal process and explained to me what my rights were. Thank you for being there, things are better now.
Gordon Rios
7 years ago
5 Star Reviews 150
It was a great pleasure working with Michelle Josama
Danielle Denese
5 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038